Higher rates of triglyceride metabolism have recently been linked to increased all-cause, cardiovascular, cancer, and other mortality, but what does it mean for practising clinicians? Professor Børge G. Nordestgaard (University of Copenhagen, Denmark) discusses the new findings and their potential implications.
Volanesorsen meta-analysis shows acute pancreatitis decrease in hypertriglyceridaemia
Volanesorsen reduces acute pancreatitis in patients with severe hypertriglyceridaemia, according to results of a fixed-effects meta-analysis of individual patient data from three randomised, controlled trials that included patients with a TG level of >500 mg/dL (5.6 mmol/L).1-3 Of the 207 patients in the analysis, reported in the New England Journal of Medicine, 121 received volanesorsen […]
Should TG cut-off for CV risk be lower?
A lower than conventional prognostic cut-off value for TG for CV events has emerged from an analysis of data from a large regional Italian cohort of 14,189 patients aged 18-95 years followed up for 11.2 (5.3-13.2) years. A conventional cut-off value for TG (150 mg/dL [1.7 mmol/L]) and prognostic cut-offs identified from a receiver operating characteristic […]
Are remnants more atherogenic than LDL? Novel genetic insights
Elias Björnson, University of Gothenburg, Sweden, discusses data from a UK Biobank Study which investigated the association between triglyceride-rich lipoproteins/remnant cholesterol and risk of coronary heart disease, and the atherogenicity of those particles compared to low-density lipoprotein particles.
NICU babies need targeted TG monitoring
Premature babies receiving TG containing nutrition in neonatal intensive care units (NICU) need individualised TG monitoring, according to researchers who compared TG levels in neonates stratified by gestational age (GA), birth weight (BW), and growth restriction status. From 2018 to 2021, 427 infants born at <32 weeks GA or with BW <1,500 gm were included […]
Fresh support for remnant cholesterol measurement and management
Results of two recent studies linking elevated remnant cholesterol (RC) to premature mortality and atherosclerotic cardiovascular disease (ASCVD) have raised the question of whether RC should be included in risk stratification and as a treatment target.